Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | Trastuzumab |
| Synonyms | |
| Therapy Description |
Herceptin (trastuzumab) is a monoclonal antibody, which binds ERBB2 (HER2) to induce tumor cellular cytotoxicity (PMID: 17611206). Herceptin (trastuzumab) is FDA approved for HER2-overexpressing (or amplification) breast cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma (FDA.gov). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Trastuzumab | Herceptin | Anti HER2 | HER2 (ERBB2) Antibody 36 | Herceptin (trastuzumab) is a monoclonal antibody, which binds ERBB2 (HER2) to induce tumor cellular cytotoxicity (PMID: 17611206). Herceptin (trastuzumab) is FDA approved for HER2-overexpressing (or amplification) breast cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma (FDA.gov). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ERBB2 over exp | Her2-receptor positive breast cancer | sensitive | Trastuzumab | FDA approved - On Companion Diagnostic | Actionable | Herceptin (trastuzumab) is FDA approved as an adjuvant treatment for ERBB2 (HER2)-overexpressing (or amplification) breast cancer patients and for metastatic ERBB2 (HER2)-overexpressing (or amplification) breast cancer patients as indicated by an FDA approved companion diagnostic (FDA.gov). | detail... detail... |
| ERBB2 over exp | Her2-receptor positive breast cancer | sensitive | Trastuzumab | Guideline | Actionable | Herceptin (trastuzumab) combined with a taxane, such as Taxotere (docetaxel) or Taxol (paclitaxel), is included in guidelines as neoadjuvant therapy for patients with ERBB2 (HER2)-positive early breast cancer or as first-line therapy for patients with ERBB2 (HER2)-positive advanced breast cancer (PMID: 31236598, PMID: 30032243; ESMO.org). | detail... 31236598 30032243 |
| ERBB2 mutant | lung non-small cell carcinoma | no benefit | Trastuzumab | Guideline | Actionable | Herceptin (trastuzumab) is not recommended as a monotherapy in guidelines for non-small cell lung cancer patients with ERBB2 mutations (NCCN.org). | detail... |
| ERBB2 A775_G776insYVMA PIK3CA R425L | lung non-small cell carcinoma | predicted - resistant | Trastuzumab | Case Reports/Case Series | Actionable | In a clinical study, the PIK3CA R425L mutation was identified as a potential resistance mechanism in a non-small cell lung carcinoma patient harboring ERBB2 (HER2) A775_G776insYVMA, that progressed during Herceptin (trastuzumab) treatment (PMID: 28167203). | 28167203 |
| ERBB2 G660R | Advanced Solid Tumor | predicted - sensitive | Trastuzumab | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) G660R demonstrated decreased cell proliferation and reduced survival when treated with Herceptin (trastuzumab) in culture (PMID: 30449325). | 30449325 |
| ERBB2 amp | stomach cancer | sensitive | Trastuzumab | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Herceptin (trastuzumab) inhibited tumor growth in human cell line xenograft models of gastric cancer with ERBB2 (HER2) amplification (PMID: 26296355). | 26296355 |
| ERBB2 over exp | esophagus adenocarcinoma | sensitive | Trastuzumab | Guideline | Actionable | Herceptin (trastuzumab), in combination with first-line chemotherapy with fluoropyrimidine and cisplatin or other chemotherapy agents, but not anthracyclines, is included in guidelines for Erbb2 (Her2)-overexpressing metastatic esophageal adenocarcinoma patients (NCCN.org) | detail... |
| ARID1A loss | Her2-receptor positive breast cancer | resistant | Trastuzumab | Preclinical - Cell culture | Actionable | In a preclinical study, ERBB2 (HER2) positive breast cancer cells with ARID1A loss demonstrated resistance to Herceptin (trastuzumab) in culture (PMID: 27172896). | 27172896 |
| ERBB2 over exp PIK3CA H1047L | stomach cancer | predicted - resistant | Trastuzumab | Clinical Study - Cohort | Actionable | In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified PIK3CA mutations in 15% (3/20) of patients demonstrating primary resistance to Herceptin (trastuzumab), including 1 patient harboring PIK3CA H1047L (PMID: 29208673). | 29208673 |
| ERBB2 amp | Her2-receptor positive breast cancer | sensitive | Trastuzumab | Clinical Study - Meta-analysis | Actionable | In a meta-analysis, breast cancer patients with >12 copies of ERBB2 (HER2) had a better response to Herceptin (trastuzumab) than patients with 6-12 copies of ERBB2 (HER2) (PMID: 24691421). | 24691421 |
| ERBB2 amp | Her2-receptor positive breast cancer | sensitive | Trastuzumab | Guideline | Actionable | Herceptin (trastuzumab) combined with a taxane, such as Taxotere (docetaxel) or Taxol (paclitaxel), is included in guidelines as neoadjuvant therapy for ERBB2 (HER2)-positive patients with early breast cancer or as first-line therapy for ERBB2 (HER2)-positive patients with advanced breast cancer (PMID: 31236598, PMID: 30032243; ESMO.org). | 31236598 detail... 30032243 |
| ERBB2 amp | Her2-receptor positive breast cancer | sensitive | Trastuzumab | FDA approved - On Companion Diagnostic | Actionable | Herceptin (trastuzumab) is FDA approved as an adjuvant treatment for ERBB2 (HER2)-overexpressing (or amplification) breast cancer patients and for metastatic ERBB2 (HER2)-overexpressing (or amplification) breast cancer patients as indicated by an FDA approved companion diagnostic (FDA.gov). | detail... detail... |
| ERBB2 G660D | Advanced Solid Tumor | sensitive | Trastuzumab | Preclinical | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) G660D treated with Herceptin (trastuzumab) demonstrated decreased proliferation, reduced survival, and inhibition of colony formation in culture, and in mouse models led to improved survival compared to control models with wild-type ERBB2 (HER2) (PMID: 30449325). | 30449325 |
| ERBB2 L866M ERBB2 amp | colorectal cancer | resistant | Trastuzumab | Preclinical | Actionable | In a preclinical study, Herceptin (trastuzumab) had no effect on tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) L866M and ERBB2 (HER2) amplification (PMID: 26243863). | 26243863 |
| ERBB2 V773L | breast cancer | sensitive | Trastuzumab | Preclinical - Cell culture | Actionable | In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) V773L were sensitive to Herceptin (trastuzumab) in culture, resulting in decreased colony formation (PMID: 27697991). | 27697991 |
| ERBB2 K753E | breast cancer | resistant | Trastuzumab | Preclinical - Cell culture | Actionable | In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) K753E were resistant to Herceptin (trastuzumab) in culture (PMID: 27697991). | 27697991 |
| ERBB2 L663P | Advanced Solid Tumor | predicted - sensitive | Trastuzumab | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) L663P demonstrated decreased cell proliferation and reduced survival when treated with Herceptin (trastuzumab) in culture (PMID: 30449325). | 30449325 |
| ERBB2 D769Y ERBB2 amp | Her2-receptor positive breast cancer | resistant | Trastuzumab | Preclinical - Pdx | Actionable | In a preclinical study, a breast cancer patient-derived xenograft (PDX) model with ERBB2 (HER2) amplification and ERBB2 D769Y was refractory to treatment with Herceptin (trastuzumab) (PMID: 30301790). | 30301790 |
| ERBB2 L768S | breast cancer | sensitive | Trastuzumab | Preclinical - Cell culture | Actionable | In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) L768S were sensitive to Herceptin (trastuzumab) in culture, resulting in decreased colony formation (PMID: 27697991). | 27697991 |
| ERBB2 amp | gastroesophageal junction adenocarcinoma | sensitive | Trastuzumab | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (ToGA) that supported FDA approval, patients with either gastric cancer or gastroesophageal junction adenocarcinoma with ERBB2 (HER2) overexpression or ERBB2 (HER2) amplification had increased overall survival (13.8 mo vs 11.1 mo) when treated with Herceptin (trastuzumab) in combination with chemotherapy compared to chemotherapy alone (PMID: 20728210; NCT01041404). | 20728210 detail... detail... |
| ERBB2 V777L | colon cancer | resistant | Trastuzumab | Preclinical | Actionable | In a preclinical study, transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V777L were resistant to Herceptin (trastuzumab) in culture (PMID: 26243863). | 26243863 |
| ERBB2 G778_P780dup | breast cancer | resistant | Trastuzumab | Preclinical | Actionable | In a preclinical study, transformed human breast cell lines expressing ERBB2 P780_Y781insGSP demonstrated resistance when treated with Herceptin (trastuzumab) (PMID: 23220880). | 23220880 |
| ERBB2 S310F | urinary bladder cancer | no benefit | Trastuzumab | Preclinical - Cell culture | Actionable | In a preclinical study, a bladder cancer cell line harboring ERBB2 S310F did not demonstrate decreased viability when treated with Herception (trastuzumab) in culture (PMID: 31635022). | 31635022 |
| ERBB2 G309A | breast cancer | sensitive | Trastuzumab | Preclinical | Actionable | In a preclinical study, transformed human breast cell lines expressing ERBB2 G309A reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880). | 23220880 |
| ERBB2 S310F | breast cancer | resistant | Trastuzumab | Preclinical - Cell culture | Actionable | In a preclinical study, ligand-activated breast cancer cells expressing ERBB2 (HER2) S310F demonstrated resistance to treatment with Herceptin (trastuzumab) in culture (PMID: 31920346). | 31920346 |
| ERBB2 Q709L | Advanced Solid Tumor | predicted - sensitive | Trastuzumab | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Q709L demonstrated decreased cell proliferation and reduced survival when treated with Herceptin (trastuzumab) in culture (PMID: 30449325). | 30449325 |
| ERBB2 S310Y | colorectal cancer | sensitive | Trastuzumab | Preclinical | Actionable | In a preclinical study, Herceptin (trastuzumab) delayed tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863). | 26243863 |
| ERBB2 over exp PIK3CA H1047R | Her2-receptor positive breast cancer | resistant | Trastuzumab | Preclinical | Actionable | In a preclinical study, mouse breast cancer models over expressing ERBB2 (HER2) and expressing PIK3CA H1047R were resistant to Herceptin (trastuzumab) (PMID: 23940356). | 23940356 |
| ERBB2 L755S ERBB2 amp | Her2-receptor positive breast cancer | decreased response | Trastuzumab | Preclinical - Cell culture | Actionable | In a preclinical study, breast cancer cell lines with ERBB2 (HER2) amplification and expressing ERBB2 L755S demonstrated decreased inhibition proliferation compared to cells expressing wild-type ERBB2 (HER2) following treatment with Herceptin (trastuzumab) (PMID: 30301790). | 30301790 |
| ERBB2 V842I | colon cancer | resistant | Trastuzumab | Preclinical | Actionable | In a preclinical study, transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V842I were resistant to Herceptin (trastuzumab) in culture (PMID: 26243863). | 26243863 |
| ERBB2 R678Q | Advanced Solid Tumor | predicted - sensitive | Trastuzumab | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) R678Q demonstrated decreased cell proliferation and reduced survival when treated with Herceptin (trastuzumab) in culture (PMID: 30449325). | 30449325 |
| ERBB2 V777L | breast cancer | sensitive | Trastuzumab | Preclinical | Actionable | In a preclinical study, transformed human breast cell lines expressing ERBB2 V777L reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880). | 23220880 |
| ERBB2 V842I | breast cancer | sensitive | Trastuzumab | Preclinical | Actionable | In a preclinical study, transformed human breast cell lines expressing ERBB2 V842I reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880). | 23220880 |
| ERBB2 positive | salivary gland cancer | sensitive | Trastuzumab | Guideline | Actionable | ERBB2 (HER2)-targeted therapy, including Herceptin (trastuzumab) is included in guidelines for patients with ERBB2 (HER2)-positive salivary gland tumors with distant metastases (NCCN.org). | detail... |
| ERBB2 D769Y | breast cancer | sensitive | Trastuzumab | Preclinical | Actionable | In a preclinical study, transformed human breast cell lines expressing ERBB2 D769Y reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880). | 23220880 |
| ERBB2 pos PIK3CA mut | Her2-receptor positive breast cancer | decreased response | Trastuzumab | Clinical Study - Cohort | Actionable | In a clinical study, a retrospective analysis of Herceptin (trastuzumab) treatment in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 28177460). | 28177460 |
| ERBB2 amp | gastric adenocarcinoma | sensitive | Trastuzumab | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (ToGA) that supported FDA approval, patients with either gastric or gastroesophageal junction adenocarcinoma with ERBB2 (HER2) overexpression or ERBB2 (HER2) amplification had increased overall survival (13.8 mo vs 11.1 mo) when treated with Herceptin (trastuzumab) in combination with chemotherapy compared to chemotherapy alone (PMID: 20728210; NCT01041404). | detail... 20728210 detail... |
| ERBB2 L866M | colon cancer | sensitive | Trastuzumab | Preclinical | Actionable | In a preclinical study, Herceptin (trastuzumab) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L866M in culture (PMID: 26243863). | 26243863 |
| ERBB2 T798M ERBB2 amp | breast cancer | resistant | Trastuzumab | Preclinical - Cell line xenograft | Actionable | In a preclinical study, a human ERBB2-amplified breast cancer cell line expressing ERBB2 (HER2) T798M was resistant to Herceptin (trastuzumab) in culture and in xenograft models (PMID: 23948973). | 23948973 |
| ERBB2 R896C | breast cancer | sensitive | Trastuzumab | Preclinical | Actionable | In a preclinical study, transformed human breast cell lines expressing ERBB2 R896C reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880). | 23220880 |
| ERBB2 D769H | breast cancer | sensitive | Trastuzumab | Preclinical | Actionable | In a preclinical study, transformed human breast cell lines expressing ERBB2 D769H reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880). | 23220880 |
| ERBB2 S310F | colon cancer | sensitive | Trastuzumab | Preclinical | Actionable | In a preclinical study, Herceptin (trastuzumab) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) S310F in culture (PMID: 26243863). | 26243863 |
| ERBB2 over exp PIK3CA H1047R | stomach cancer | predicted - resistant | Trastuzumab | Clinical Study - Cohort | Actionable | In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified PIK3CA mutations in 15% (3/20) of patients demonstrating primary resistance to Herceptin (trastuzumab), including 1 patient harboring PIK3CA H1047R (PMID: 29208673). | 29208673 |
| ERBB2 over exp PIK3CA N345T | stomach cancer | predicted - resistant | Trastuzumab | Clinical Study - Cohort | Actionable | In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified PIK3CA mutations in 15% (3/20) of patients demonstrating primary resistance to Herceptin (trastuzumab), including 1 patient harboring PIK3CA N345T (PMID: 29208673). | 29208673 |
| ERBB2 over exp | gastric adenocarcinoma | sensitive | Trastuzumab | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (ToGA) that supported FDA approval, patients with either gastric or gastroesophageal junction adenocarcinoma with ERBB2 (HER2) overexpression or ERBB2 (HER2) amplification had increased overall survival (13.8 mo vs 11.1 mo) when treated with Herceptin (trastuzumab) in combination with chemotherapy compared to chemotherapy alone (PMID: 20728210; NCT01041404). | 20728210 detail... detail... |
| ERBB2 over exp | gastric adenocarcinoma | sensitive | Trastuzumab | Guideline | Actionable | Herceptin (trastuzumab) in combination with fluoropyrimidine and cisplatin (category 1) or other platinum agents (category 2A), but not anthracyclines, is included in guidelines as first-line therapy for Erbb2 (Her2)-overexpressing metastatic gastric adenocarcinoma patients (NCCN.org) | detail... |
| ERBB2 V659E | Advanced Solid Tumor | predicted - sensitive | Trastuzumab | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) V659E demonstrated decreased cell proliferation and reduced survival when treated with Herceptin (trastuzumab) in culture (PMID: 30449325). | 30449325 |
| ERBB2 pos PIK3CA act mut | Her2-receptor positive breast cancer | decreased response | Trastuzumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation due to PTEN loss and/or PIK3CA activating mutation demonstrated a decreased median progression-free survival of 4.5 months, compared to 9.0 months for patients without PI3K pathway activation following treatment with a Herceptin (trastuzumab) containing regimen (PMID: 21676217). | 21676217 |
| ERBB2 pos PIK3CA act mut | Her2-receptor positive breast cancer | decreased response | Trastuzumab | Clinical Study - Cohort | Actionable | In a clinical study, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation resulting from low PTEN expression and/or PIK3CA activating mutations demonstrated decreased progression-free survival following treatment with Herceptin (trastuzumab) compared to patients without PI3K pathway activation (PMID: 17936563). | 17936563 |
| ERBB2 over exp | gastroesophageal junction adenocarcinoma | sensitive | Trastuzumab | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (ToGA) that supported FDA approval, patients with either gastric cancer or gastroesophageal junction adenocarcinoma with ERBB2 (HER2) overexpression or ERBB2 (HER2) amplification had increased overall survival (13.8 mo vs 11.1 mo) when treated with Herceptin (trastuzumab) in combination with chemotherapy compared to chemotherapy alone (PMID: 20728210; NCT01041404). | 20728210 detail... detail... |
| ERBB2 over exp | gastroesophageal junction adenocarcinoma | sensitive | Trastuzumab | Guideline | Actionable | Herceptin (trastuzumab), in combination with fluoropyrimidine and cisplatin, or other chemotherapy agents, but not anthracyclines, is included in guidelines for Erbb2 (Her2)-overexpressing metastatic esophagogastric junction adenocarcinoma patients (NCCN.org) | detail... |
| ERBB2 amp | colorectal cancer | resistant | Trastuzumab | Preclinical | Actionable | In a preclinical study, colorectal cancer tumorgrafts with ERBB2 (HER2) amplification demonstrated resistance to Herceptin (trastuzumab) treatment in animal models (PMID: 26296355). | 26296355 |
| ERBB2 L755S | colon cancer | sensitive | Trastuzumab | Preclinical | Actionable | In a preclinical study, Herceptin (trastuzumab) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863). | 26243863 |
| ERBB2 exon 20 ins | lung non-small cell carcinoma | predicted - sensitive | Trastuzumab | Case Reports/Case Series | Actionable | In a clinical study, targeted therapy with Gilotrif (afatinib) or Herceptin (trastuzumab) resulted in an objective response rate of 44% (4/9) in non-small cell lung carcinoma patients harboring ERBB2 (HER2) mutations that progressed during previous therapies, all four responders harbored ERBB2 (HER2) exon 20 insertions (PMID: 28167203). | 28167203 |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status |
|---|---|---|---|---|
| NCT02213289 | Phase Ib/II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Docetaxel + Fluorouracil Trastuzumab Fluorouracil + Irinotecan + Leucovorin Rilotumumab | PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression | Active, not recruiting |
| NCT02774681 | Phase II | Trastuzumab Palbociclib | Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis | Terminated |
| NCT02924883 | Phase II | Trastuzumab Atezolizumab + Trastuzumab | A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy (KATE2) | Completed |
| NCT02229149 | Phase II | Paclitaxel Docetaxel Pertuzumab + Trastuzumab Nab-paclitaxel Vinorelbine Trastuzumab Capecitabine | Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer | Active, not recruiting |
| NCT01480583 | Phase II | Trastuzumab | GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases | Completed |
| NCT00968968 | Phase III | Trastuzumab Lapatinib + Trastuzumab | Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone | Terminated |
| NCT01928290 | Phase II | Trastuzumab Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer | Active, not recruiting |
| NCT03521245 | Phase I | Trastuzumab | Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer | Recruiting |
| NCT01367002 | Phase II | Trastuzumab Carboplatin + Paclitaxel | Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer | Active, not recruiting |
| NCT01875666 | Phase I | Lapatinib + Trastuzumab Trastuzumab Pertuzumab Pertuzumab + Trastuzumab | Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib | Completed |
| NCT01904903 | Phase II | Pertuzumab Ado-trastuzumab emtansine Trastuzumab | Cardiac Safety Study in Patients With HER2+ Breast Cancer (SAFE-HEaRt) | Active, not recruiting |
| NCT01358877 | Phase III | Pertuzumab Trastuzumab | A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer | Active, not recruiting |
| NCT02297698 | Phase II | Sargramostim Trastuzumab E75 | Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients | Active, not recruiting |
| NCT03432741 | Phase I | Carfilzomib Daratumumab Obinutuzumab Gemcitabine Trastuzumab Romidepsin Nivolumab Rituximab Belinostat Pembrolizumab | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer | Suspended |
| NCT02286843 | Phase I | Trastuzumab | Can HER2 Targeted 89Zr-trastuzumab PET/CT Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy? | Active, not recruiting |
| NCT01106898 | Phase II | Cyclophosphamide + Paclitaxel Trastuzumab | Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Treating Women With Stage I or Stage II Breast Cancer Who Have Undergone Surgery | Completed |
| NCT02213042 | Phase II | Lapatinib + Trastuzumab Trastuzumab | Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer | Active, not recruiting |
| NCT01772472 | Phase III | Ado-trastuzumab emtansine Trastuzumab | A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) | Active, not recruiting |
| NCT01566721 | Phase III | Trastuzumab | A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer) | Completed |
| NCT00912340 | Phase II | Everolimus Trastuzumab | Randomized Phase II Trial of Trastuzumab or EVEROLIMUS in Hormone-refractory Metastatic Breast Cancer | Completed |
| NCT02571530 | Phase I | Trastuzumab | Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer | Recruiting |
| NCT01491737 | Phase II | Anastrozole Letrozole Trastuzumab Pertuzumab + Trastuzumab | A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer (PERTAIN) | Completed |
| NCT02260531 | Phase II | Cabozantinib Trastuzumab | Cabozantinib + / - Trastuzumab In Breast Cancer Patients w/ Brain Metastases | Active, not recruiting |
| NCT01325207 | Phase Ib/II | Trastuzumab | Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer | Completed |
| NCT02390427 | Phase I | Trastuzumab Paclitaxel Pertuzumab Taselisib | Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer | Active, not recruiting |
| NCT03379428 | Phase Ib/II | Trastuzumab Ibrutinib + Trastuzumab | Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer | Recruiting |
| NCT00796978 | Phase II | Trastuzumab | Trastuzumab in Treating Older Women With Early-Stage Breast Cancer | Active, not recruiting |
| NCT02675231 | Phase II | Trastuzumab Abemaciclib + Trastuzumab Abemaciclib + Fulvestrant + Trastuzumab | A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer (monarcHER) | Active, not recruiting |
| NCT00574587 | Phase Ib/II | Paclitaxel + Vorinostat Trastuzumab Cyclophosphamide + Doxorubicin | Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis | Unknown status |
| NCT01570036 | Phase II | E75 Sargramostim Trastuzumab | Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax | Completed |
| NCT02336984 | Phase Ib/II | Trastuzumab HER2-pulsed DC1 vaccine | A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS | Active, not recruiting |
| NCT01750073 | Phase II | Doxorubicin Trastuzumab Cyclophosphamide + Paclitaxel | Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Stage I-III Breast Cancer | Recruiting |
| NCT02947685 | Phase III | Fulvestrant Pertuzumab Letrozole Anastrozole Exemestane Trastuzumab | Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA) | Recruiting |
| NCT02492711 | Phase III | Vinorelbine Capecitabine Gemcitabine Trastuzumab Eribulin Margetuximab | Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer | Active, not recruiting |
| NCT01779050 | Phase II | Trastuzumab Docetaxel Cyclophosphamide + Epirubicin Paclitaxel Cyclophosphamide + Epirubicin + Fluorouracil Carboplatin + Docetaxel Cyclophosphamide + Docetaxel | Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells | Active, not recruiting |
| NCT01912963 | Phase II | Eribulin Pertuzumab Trastuzumab | Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer | Terminated |
| NCT01160211 | Phase III | Lapatinib + Trastuzumab Letrozole Anastrozole Lapatinib Trastuzumab Exemestane | A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer | Active, not recruiting |
| NCT02657343 | Phase Ib/II | Ribociclib Trastuzumab Ado-trastuzumab emtansine | An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. | Active, not recruiting |
| NCT00971737 | Phase II | Trastuzumab Cyclophosphamide | Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer | Completed |
CKB BOOST